BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GenVec Inc. (GNVC) Reports Preclinical Research At American Association for Cancer Research Showing TNFerade Effective Against Metastases In Melanoma Model And Demonstrating Targeting In Ovarian Cancer Model


10/19/2005 5:13:13 PM

GAITHERSBURG, Md.--(BUSINESS WIRE)--April 20, 2005--GenVec, Inc. (Nasdaq:GNVC) announced the presentation of two posters at the American Association for Cancer Research (AACR), currently ongoing in Anaheim, California. The first poster, "Local Therapy with TNFerade(TM) and Radiation Suppresses Metastatic Disease in the Spontaneously Metastatic B16F10 Melanoma Model," showed that TNFerade significantly reduced the spread (metastasis) of the cancer to lymph nodes in a mouse model of melanoma. In a second poster, researchers from GenVec and its partner, Fuso Pharmaceutical Industries Ltd. of Japan, presented preclinical data demonstrating successful targeting and efficacious treatment in an ovarian cancer mouse model using a next generation targeted vector to deliver the tumor necrosis factor-alpha (TNF-alpha) gene. This poster is entitled "Tumor Targeting of Adenoviral Vectors Combined with Selective TNF Gene Expression is Effective and Well-Tolerated in Models of Ovarian Cancer." Both research posters are accessible through the company's website.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES